Alnylam Pharmaceuticals
ALNY
#378
Rank
NZ$104.76 B
Marketcap
NZ$793.01
Share price
-1.55%
Change (1 day)
82.03%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): NZ$0.31

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is NZ$0.16. In 2023 the company made an earnings per share (EPS) of NZ-$6.11 an increase over its 2022 EPS that were of NZ-$16.08.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)NZ$0.31
2023NZ-$6.11-62%
2022NZ-$16.0829.03%
2021NZ-$12.46-3.36%
2020NZ-$12.90-8.48%
2019NZ-$14.097.67%
2018NZ-$13.0939.74%
2017NZ-$9.3612.94%
2016NZ-$8.2938.84%
2015NZ-$5.97-32.88%
2014NZ-$8.90259.44%
2013NZ-$2.48-31.25%
2012NZ-$3.60

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Arrowhead Pharmaceuticals
ARWR
NZ-$2.16-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
NZ$75.19 48,166.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
NZ-$4.74-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
NZ-$0.42-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
NZ-$1.26-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
NZ$12.74 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$6.41 4,017.43%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
NZ$1.09 600.00%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel